| Primary information |
|---|
| ThPP ID | Th1237 |
| Therapeutic Peptide/Protein Name | Somatropin recombinant |
| Sequence | FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT view full sequnce in fasta |
| Functional Classification | Ib |
| Molecular Weight | 22129 |
| Chemical Formula | C990H1532N262O300S7 |
| Isoelectric Point | 5.27 |
| Hydrophobicity | -0.411 |
| Melting Point (℃) | 76 °C at |
| Half Life | NA |
| Description | Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli |
| Indication/Disease | For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss |
| Pharmacodynamics | Used in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor). |
| Mechanism of Action | hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | 2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)] |
| Categories | Hormones, Hormone Substitutes, and Hormone Antagonists |
| Patents Number | CA1326439,CA2252535 |
| Date of Issue | Mostly fro |
| Date of Expiry | Mostly 202 |
| Drug Interaction | The therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Bazedoxifene, Chlorotrianisene, Conjugated Equine Estrogens, Cortisone acetate, Dienestrol, Diethylstilbestrol, Estradiol, Estriol, Estrone, Ethinyl Estradiol. |
| Target | Growth hormone receptor, Prolactin receptor |
| Information of corresponding available drug in the market |
|---|
| Brand Name | BioTropin |
| Company | Biotech General |
| Brand Discription | Bitropin is a recombinant human growth hormone |
| Prescribed for | It is indicate dfor short stature due to pitutary growth hormone deficency, turner Syndorme, Children suffering from renal insuuficiency. |
| Chemical Name | NA |
| Formulation | NA |
| Physcial Appearnce | Powder and Solvent for Solution |
| Route of Administration | Subcutaneous |
| Recommended Dosage | The reequired dose is 10mg/ml |
| Contraindication | children with closed epiphyses. |
| Side Effects | may lead to loss or increase of adipose tissue as well as punctual haemorrhage and bruising at the injection site. |
| Useful Link | https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Bio_Tropin_10mg_dr_1316590559720.pdf , https://www.drugbank.ca/drugs/DB00052 |
| PubMed ID | 2688, 2903866, 16702112, 5675428 |
| 3-D Structure | N.A. |